Maryam B Lustberg MD, MPH

Maryam B Lustberg MD, MPH
Asst ProfessorCollege of Medicinelustberg.3@osu.edu
B421 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-366-8541Fax: 614-293-7529
  • Cancer Control

Current Publications

  • Loprinzi CLPrevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.J Clin Oncol 4/14/2014
  • Shapiro CLPhase II Trial of Neoadjuvant Weekly Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Biweekly Bevacizumab Therapy in Women With Clinical Stage II or III HER2-Negative Breast Cancer.Clin Breast Cancer 2/20/2014
  • Wu Y, Deighan CJ, Miller BL, Balasubramanian P, Lustberg MB, Zborowski M, Chalmers JJIsolation and analysis of rare cells in the blood of cancer patients using a negative depletion methodology.Methods 64 169-82 12/1/2013
  • Aggarwal R, Lu J, Kanji S, Das M, Joseph M, Lustberg MB, Ray A, Pompili VJ, Shapiro CL, Das HHuman V?2Vd2 T cells limit breast cancer growth by modulating cell survival-, apoptosis-related molecules and microenvironment in tumors.Int J Cancer 133 2133-44 11/1/2013
  • Wenzell CM, Berger MJ, Blazer MA, Crawford BS, Griffith NL, Wesolowski R, Lustberg MB, Phillips GS, Ramaswamy B, Mrozek E, Flynn JM, Shapiro CL, Layman RMPilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.Support Care Cancer 21(10) 2845-51 10/1/2013
  • Shapiro CLSevere and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer.Cancer Chemother Pharmacol 71(5) 1183-90 5/1/2013
  • Lustberg MBManagement of neutropenia in cancer patients.Clin Adv Hematol Oncol 10(12) 825-6 12/1/2012
  • Lustberg MB, Reinbolt RE, Shapiro CLBone health in adult cancer survivorship.J Clin Oncol 30(30) 3665-74 10/20/2012
  • Yang X, Mrozek E, Lustberg M, Jia G, Sammet S, Sammet C, Shapiro C, Knopp MVMicrocirculatory fraction (MCF(I)) as a potential imaging marker for tumor heterogeneity in breast cancer.Magn Reson Imaging 30(8) 1059-67 10/1/2012
  • Berger MJ, Dunlea LJ, Rettig AE, Lustberg MB, Phillips GS, Shapiro CLFeasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.Support Care Cancer 20(9) 1991-7 9/1/2012
  • Lustberg MB, Pant S, Ruppert AS, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen RR, Berger M, Mrozek E, Ramaswamy B, Grever M, Au JL, Wientjes MG, Shapiro CLPhase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.Cancer Chemother Pharmacol 70(1) 49-56 7/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu